fibroblast growth factor 23
Zuletzt aktualisiert 16 Mar 2026
Erfüllt die redaktionelle Richtlinien
- HerunterladenHerunterladen
- Teilen
- Language
- Diskussion
- Audio-Version
- Zu bevorzugten Quellen bei Google hinzufügen
The FGF23 gene provides instructions for making a protein called fibroblast growth factor 23, which is produced in bone cells. This protein helps regulate phosphate levels within the body. Among its many functions, phosphate plays a critical role in the formation and growth of bones during childhood and helps maintain bone strength in adults.
Normal function
The FGF23 gene provides instructions for making a protein called fibroblast growth factor 23, which is produced in bone cells. This protein helps regulate phosphate levels within the body. Among its many functions, phosphate plays a critical role in the formation and growth of bones during childhood and helps maintain bone strength in adults.
Fibroblast growth factor 23 works in the kidneys to keep the body's phosphate levels in balance. The kidneys normally release excess phosphate in the urine, and they reabsorb this mineral into the bloodstream when more is needed. Fibroblast growth factor 23 acts as a signal that tells the kidneys to stop reabsorbing phosphate into the bloodstream.
In order for fibroblast growth factor 23 to function, sugar molecules must attach to the protein through a process called glycosylation. This allows fibroblast growth factor 23 to move out of the bone cell and protects it from being broken down. Once outside the cell, fibroblast growth factor 23 must bind to a receptor protein that spans the membrane of kidney cells. Binding to this receptor triggers a signaling pathway that stops phosphate reabsorption by the kidneys. When more phosphate is needed, fibroblast growth factor 23 is cut (cleaved) at a certain site, which turns off (inactivates) the protein. This helps regulate the amount of active fibroblast growth factor 23 that is circulating in the bloodstream.
Conditions referring to this gene or chromosome
Related patient information and medicines
Patient information leaflet
Lokalisierte Sklerodermie
Localised scleroderma causes one or more patches of hard skin. There are different types. Generalised morphoea symptoms This is a ... Causes of localised scleroderma The cause is not clear. What is known is that cells genannt fibroblasts make too much of a protein genannt collagen. The collagen gets deposited in the skin, causing scarring and.
Patient information leaflet
Diabetische Retinopathie
Stage 2: pre-proliferative retinopathy Pre-proliferative retinopathy is m... There are signs of blood flow becoming restricted but not yet showing new blood vessels growing (see below). Stage 3: proliferative retinopathy Proliferative retinopathy is the advanced diabetic retinopathy that occurs when damaged blood vessels in the retina make.
Patient information leaflet
Blasenmole
(They are 'non-viable' pregnancies.). A pregnancy that results in a hydatidiform mole is called a molar pregnancy. A molar Schwangerschaft is part of a group of disorders genannt gestational trophoblastic disease (GTD). Der trophoblast is the outer layer of cells around an embryo, which normally grows into the placenta and the membranes surrounding the.
Patient information leaflet
Chronische Sinusitis
Other medical conditions Sometimes, chronic sinusitis can develop as a result of another medical condition. Examples include: Cystic fibrosis , ein genetic condition which causes thick mucus that is difficult to clear from the lungs, sinuses, and elsewhere. Granulomatosis with polyangiitis , a rare condition causing inflammation of blood vessels..
Patient information leaflet
Brustkrebs
They. Invasive lobular breast cancers begins in one of the lobes of the breast. They account for about 1 in 10 of invasive breast cancers. Overall, about 7 in 10 breast cancers are oestrogen receptor positive. Treatment can block the oestrogen in these cancers (see below). Human epidermal growth factor (HER2) is a protein that can affect the.
Patient information leaflet
Kehlkopfkrebs
It is thought that something damages or changes certain genes in the cell. This makes the cell multiply out of control and become cancerous. See the sepa... It is a type of monoclonal antibody which means that it can recognise and bind to specific proteins (receptors) that are found in the cancer cells. These proteins are epidermal growth factor.
Weiterführende Lektüre und Referenzen
- fibroblast growth factor 23; MedlinePlus, National Library of Medicine.
- ADHR Consortium. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet. 2000 Nov;26(3):345-8. doi: 10.1038/81664.
- Bergwitz C, Juppner H. Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23. Annu Rev Med. 2010;61:91-104. doi: 10.1146/annurev.med.051308.111339.
- Courbebaisse M, Lanske B. Biology of Fibroblast Growth Factor 23: From Physiology to Pathology. Cold Spring Harb Perspect Med. 2018 May 1;8(5):a031260. doi: 10.1101/cshperspect.a031260.
- Farrow EG, Imel EA, White KE. Miscellaneous non-inflammatory musculoskeletal conditions. Hyperphosphatemic familial tumoral calcinosis (FGF23, GALNT3 and alphaKlotho). Best Pract Res Clin Rheumatol. 2011 Oct;25(5):735-47. doi: 10.1016/j.berh.2011.10.020.
- Fukumoto S. Physiological regulation and disorders of phosphate metabolism--pivotal role of fibroblast growth factor 23. Intern Med. 2008;47(5):337-43. doi: 10.2169/internalmedicine.47.0730. Epub 2008 Mar 3.
- Garringer HJ, Malekpour M, Esteghamat F, Mortazavi SM, Davis SI, Farrow EG, Yu X, Arking DE, Dietz HC, White KE. Molecular genetic and biochemical analyses of FGF23 mutations in familial tumoral calcinosis. Am J Physiol Endocrinol Metab. 2008 Oct;295(4):E929-37. doi: 10.1152/ajpendo.90456.2008. Epub 2008 Aug 5.
- Imel EA, Econs MJ. Fibroblast growth factor 23: roles in health and disease. J Am Soc Nephrol. 2005 Sep;16(9):2565-75. doi: 10.1681/ASN.2005050573. Epub 2005 Jul 20. No abstract available.
- Quarles LD. FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization. Am J Physiol Endocrinol Metab. 2003 Jul;285(1):E1-9. doi: 10.1152/ajpendo.00016.2003.
- Ramon I, Kleynen P, Body JJ, Karmali R. Fibroblast growth factor 23 and its role in phosphate homeostasis. Eur J Endocrinol. 2010 Jan;162(1):1-10. doi: 10.1530/EJE-09-0597. Epub 2009 Sep 23.
- Razzaque MS. The FGF23-Klotho axis: endocrine regulation of phosphate homeostasis. Nat Rev Endocrinol. 2009 Nov;5(11):611-9. doi: 10.1038/nrendo.2009.196.
- Saito T, Fukumoto S. Fibroblast Growth Factor 23 (FGF23) and Disorders of Phosphate Metabolism. Int J Pediatr Endocrinol. 2009;2009:496514. doi: 10.1155/2009/496514. Epub 2009 Oct 7.
- Sprecher E. Familial tumoral calcinosis: from characterization of a rare phenotype to the pathogenesis of ectopic calcification. J Invest Dermatol. 2010 Mar;130(3):652-60. doi: 10.1038/jid.2009.337. Epub 2009 Oct 29.
Artikelverlauf
Artikel auch verfügbar in Englisch, Deutsch, Spanisch, Französisch, Italienisch, Portugiesisch, Hindi, Hebräisch, Arabisch, und Schwedisch.
16 Mar 2026 | Neueste Version
1 Mar 2026 | Ursprünglich veröffentlicht
Nehmen Sie an der Diskussion teil
Teilen Sie Ihre Gedanken oder Erfahrungen mit anderen in unserem Patientengemeinschaften.
Fragen, teilen, verbinden.
Durchsuchen Sie Diskussionen, stellen Sie Fragen und teilen Sie Erfahrungen zu Hunderten von Gesundheitsthemen.
Abonnieren Sie den Patienten-Newsletter
Ihre wöchentliche Dosis klarer, vertrauenswürdiger Gesundheitsberatung - geschrieben, um Ihnen zu helfen, sich informiert, selbstbewusst und in Kontrolle zu fühlen.
Durch das Abonnieren akzeptieren Sie unsere Datenschutzrichtlinie. Sie können sich jederzeit abmelden. Wir verkaufen Ihre Daten niemals.